Background

40% of patients are resistant to Azacitidine before the beginning of this treatment and 100% become resistant during their treatment.

The current method to measure patient’s resistance is to administer Azacitidine treatment for at least 6 months and observe effects.

→ No predictive method is available to detect therapy relapse.

→ Overexpression of BCL2L10 protein is associated to Azacitidine resistance.

Benefits

The percentage of total cells expressing BCL2L10 is simply measured in a biological sample.

With this biomarker, physicians can :

• define patients status (Azacitidine sensitive or resistant) before the beginning of their treatment ;
• monitor treatment’s relapse and early detection of resistance during treatment.

Applications

• Predictive diagnostic of patients status regarding Azacitidine sensitivity or resistance ;
• Monitoring of relapse’s risk ;
• Early detection of Azacitidine resistance induced by therapy.